Ji Li

Amministratore Delegato presso

Feixiang Chemicals (Zhangjiagang) Co., Ltd.

Process Industries

Industrial Services

Health Technology

Profilo

Dr. Ji Li is a President & Chief Executive Officer at Ufovax LLC, a Chief Executive Officer at Feixiang Chemicals (Zhangjiagang) Co., Ltd. and a President at Hipro Polymers, Inc. Dr. Li was previously employed as a Chief Executive Officer by Uvax Bio LLC, a Vice President by Solvay Specialty Chemicals Asia Pacific Pte Ltd., and a President by Suzhou HiPro Polymers Co., Ltd.

Posizioni attive di Ji Li

Società	Posizione	Inizio
Feixiang Chemicals (Zhangjiagang) Co., Ltd. Feixiang Chemicals (Zhangjiagang) Co., Ltd. Chemicals: SpecialtyProcess Industries Produces and distributes fatty specialty chemicals	Amministratore Delegato	01/02/2011
Hipro Polymers, Inc.	Presidente	01/02/2011
Ufovax LLC Ufovax LLC BiotechnologyHealth Technology Operates as biotechnology company which develops vaccines	Amministratore Delegato	01/01/2018

Tutte le posizioni attive di Ji Li

Precedenti posizioni note di Ji Li

Società	Posizione	Fine
Uvax Bio, LLC Uvax Bio, LLC Uvax Bio LLC is a biotech pharmaceutical company specializing in the development of next-generation vaccines using its proprietary 1c-sa®pnp platform, which utilizes stable, multi-layered protein nanoparticles to present rationally designed antigens that elicit broad and potent immune responses against infectious diseases. The company is based in Newark, DE. The company’s vaccine pipeline targets major health threats including HIV-1, MERS, pandemic influenza, RSV, HMPV, and Lassa fever. Uvax Bio holds exclusive worldwide rights to the 1c-sa®pnp platform and has an expanding portfolio of clinical and patented preclinical vaccine candidates. The company’s technology enables the production of virus-like protein particles that can display multiple stabilized antigens targeting a wide range of viral and bacterial diseases, produced using a single-step, universal, cell-based manufacturing process. The company was founded in 2018 by Ji Li, Jiang Zhu. Ji Li has been the CEO since 2018.	Amministratore Delegato	04/02/2025
Solvay Specialty Chemicals Asia Pacific Pte Ltd. Solvay Specialty Chemicals Asia Pacific Pte Ltd. Chemicals: SpecialtyProcess Industries Manufactures basic and performance chemicals	Corporate Officer/Principal	-
Suzhou HiPro Polymers Co., Ltd. Suzhou HiPro Polymers Co., Ltd. Oilfield Services/EquipmentIndustrial Services Manufactures and distributes bio-renewable polymades from natural resource cator oil	Presidente	-

Vedi nel dettaglio l'esperienza di Ji Li

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Ji Li

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	6
Feixiang Chemicals (Zhangjiagang) Co., Ltd. Feixiang Chemicals (Zhangjiagang) Co., Ltd. Chemicals: SpecialtyProcess Industries Produces and distributes fatty specialty chemicals	Process Industries
Suzhou HiPro Polymers Co., Ltd. Suzhou HiPro Polymers Co., Ltd. Oilfield Services/EquipmentIndustrial Services Manufactures and distributes bio-renewable polymades from natural resource cator oil	Industrial Services
Hipro Polymers, Inc.
Solvay Specialty Chemicals Asia Pacific Pte Ltd. Solvay Specialty Chemicals Asia Pacific Pte Ltd. Chemicals: SpecialtyProcess Industries Manufactures basic and performance chemicals	Process Industries
Ufovax LLC Ufovax LLC BiotechnologyHealth Technology Operates as biotechnology company which develops vaccines	Health Technology
Uvax Bio, LLC Uvax Bio, LLC Uvax Bio LLC is a biotech pharmaceutical company specializing in the development of next-generation vaccines using its proprietary 1c-sa®pnp platform, which utilizes stable, multi-layered protein nanoparticles to present rationally designed antigens that elicit broad and potent immune responses against infectious diseases. The company is based in Newark, DE. The company’s vaccine pipeline targets major health threats including HIV-1, MERS, pandemic influenza, RSV, HMPV, and Lassa fever. Uvax Bio holds exclusive worldwide rights to the 1c-sa®pnp platform and has an expanding portfolio of clinical and patented preclinical vaccine candidates. The company’s technology enables the production of virus-like protein particles that can display multiple stabilized antigens targeting a wide range of viral and bacterial diseases, produced using a single-step, universal, cell-based manufacturing process. The company was founded in 2018 by Ji Li, Jiang Zhu. Ji Li has been the CEO since 2018.

Vedi le connessioni aziendali